idecabtagene vicleucel
Drug Details
- Generic Name
- idecabtagene vicleucel
- Brand Names
- Abecma
- Application Number
- BLA125736
- Sponsor
- Celgene Corporation
- NDC Codes
- 1
- Dosage Forms
- SUSPENSION
- Routes
- INTRAVENOUS
- Active Ingredients
- IDECABTAGENE VICLEUCEL
Indications and Usage
1 INDICATIONS AND USAGE ABECMA is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. ABECMA is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. ( 1 )